Mylan has launched its lidocaine patch 5%, the generic version of Endo Pharmaceutical's Lidoderm.
Mylan has launched its lidocaine patch 5%, the generic version of Endo Pharmaceutical’s Lidoderm.
The topical product is approved as a local anesthetic for the relief of pain associated with post-herpetic neuralgia.
Mylan CEO Heather Bresch explained in a press release that the drug “comes in the form of a thin, lightweight patch and offers patients a high quality, affordable treatment option within the pain management space.”
The launch of Mylan’s lidocaine patch 5% follows Actavis’s initial generic version.
Some side effects associated with topical lidocaine include blistering, bruising, itching, and swelling. More adverse events may include seizures, irregular breathing, fast heartbeat, and fever.